Research in context
Evidence before this study
Patients who present with ST-elevation myocardial infarction (STEMI) without modifiable risk factors are not uncommon. The standard for clinical trials is to report the proportion of patients with standard modifiable cardiovascular risk factors (SMuRFs; diabetes, hypertension, hypercholesterolaemia, and smoking). On a review of the international guidelines and their referenced trials, we found an absence of data on the proportion of patients without SMuRFs. Thus, characteristics and outcomes in this group, including adherence and specific response to secondary prevention therapies, are not known. We recently reported an increase in the proportion of SMuRF-less patients with STEMI in the past decade, and in a national cohort, observed an unexpected excess in in-hospital mortality compared with patients with at least one SMuRF. Longer-term outcomes, particularly those driven by progression of atherosclerosis, are not known.
Added value of this study
This study is unprecedented in examining the characteristics and long-term outcomes in patients presenting with STEMI with no apparent SMuRFs, who are commonly assumed to be at low risk of further complications despite having atherosclerosis and life-threatening myocardial infarction with no obvious explanation. Using the comprehensive SWEDEHEART registry, we examined mortality and major adverse cardiovascular events for up to 12 years of follow-up in patients presenting with STEMI without SMuRFs. We present an unexpected finding of significant excess 30-day mortality in SMuRF-less patients, compared with patients with at least one modifiable risk factor, which would appear to compound the already poor outcomes particularly in women. The association of SMuRF-less status with increased early mortality did not appear to be driven by recurrent myocardial infraction or heart failure, and was attenuated after adjustment for use of guideline-indicated treatments targeting angiotensin and β1-adrenergic neurohormonal pathways. Detailed long-term follow-up of SWEDEHEART data showed that, although progression of atherosclerosis and recurrent myocardial infarction is considerable in patients without SMuRFs, these events are less common than in patients with SMuRFs.
Implications of all the available evidence
Evidence-based pharmacotherapy should be prescribed during the immediate post-infarct period irrespective of perceived low risk. Increased education and awareness are now needed, given that low risk for developing atherosclerosis does not seem to equate to low risk of death or atherosclerotic events after myocardial infarction, and that women without SMuRFs are at the highest risk of mortality in the first 30 days after presentation. SMuRF-less patients should be considered and represented in all clinical trials, and reported alongside the proportion of patients with each individual risk factor. Dedicated meta-analyses of clinical trial data examining the efficacy of secondary prevention pharmacotherapy in SMuRF-less patients would be valuable, and help inform guidelines regarding management of this group. The substantial number of SMuRF-less patients we identified and their high 30-day mortality rate highlights the need to find new biomarkers, to improve early identification and primary prevention of atherosclerosis, where traditional risk algorithms are currently failing.